CVS director receives 582-share stock retainer grant

Gallina John E reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Gallina John E reported acquisition or exercise transactions in this Form 4 filing.

CVS Health Corp director John E. Gallina reported receiving a grant of common stock as part of his board compensation. He was awarded 582 shares of CVS common stock on March 19, 2026 at a reference price of $71.86 per share, issued as payment of a pro rata semi-annual retainer under the 2017 Incentive Compensation Plan. Following this grant, he directly owns 582 CVS shares, reflecting a compensation-related equity award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 582 shares

Grant/Award 1 txn

Insider Gallina John E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	582	$71.86	$42K

Holdings After Transaction: Common Stock — 582 shares (Direct)

Footnotes (1)

1. F1. Consists of common stock issued in payment of a pro rata semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CVS (CVS) director John E. Gallina report?

John E. Gallina reported receiving 582 shares of CVS common stock. The shares were granted as part of his semi-annual board retainer, paid in stock under the 2017 Incentive Compensation Plan, rather than bought on the open market.

Was John E. Gallina’s CVS (CVS) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant of CVS shares to John E. Gallina. He acquired 582 common shares as a compensation award, not through an open-market purchase, with the grant tied to his semi-annual director retainer.

How many CVS (CVS) shares does John E. Gallina hold after this Form 4 filing?

After this reported transaction, John E. Gallina directly holds 582 CVS common shares. This total reflects the full amount of the latest grant, as the filing does not list any additional common stock holdings or derivative positions.

What price was used for John E. Gallina’s CVS (CVS) stock retainer grant?

The grant used a reference price of $71.86 per CVS share. According to the disclosure, the common stock was issued at the market price in payment of a pro rata semi-annual cash retainer for board service.

Under which plan was John E. Gallina’s CVS (CVS) stock award granted?

The 582-share stock award was granted under CVS Health’s 2017 Incentive Compensation Plan. The footnote explains the shares were issued in payment of a pro rata semi-annual director retainer, aligning board compensation with company equity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 05:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallina John E

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RHODE ISLAND 02895

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		A(1)		582	A	$71.86	582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of common stock issued in payment of a pro rata semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.

	/s/ John E. Gallina	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)